Korean J Intern Med.
2017 Nov;32(6):1025-1036. 10.3904/kjim.2016.094.
24-Hour blood pressure response to lower dose (30 mg) fimasartan in Korean patients with mild to moderate essential hypertension
- Affiliations
-
- 1Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea. ohbhmed@snu.ac.kr
- 2Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
- 3Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- 4Department of Internal Medicine, Kyungpook National University Hospital, Daegu, Korea.
- 5Department of Internal Medicine, The Heart Center of Chonnam National University Hospital, Gwangju, Korea.
- 6Department of Internal Medicine, Inje University Busan Paik Hospital, Busan, Korea.
- KMID: 2396762
- DOI: http://doi.org/10.3904/kjim.2016.094
Abstract
- BACKGROUND/AIMS
Fimasartan is an angiotensin type 1 receptor blocker (ARB) which has comparable efficacy and tolerability with other ARBs. The aim of this study was to evaluate 24-hour blood pressure (BP) lowering efficacy and the tolerability of the low dose fimasartan compared with valsartan in patients with mild to moderate hypertension.
METHODS
This study was a phase II, prospective, multicenter, randomized, double-blind, parallel-grouped trial. A total of 75 hypertensive patients, whose mean ambulatory BP monitoring values were ≥ 135/85 mmHg, were randomized to either fimasartan 30 mg or valsartan 80 mg daily. The primary efficacy endpoint was the change in the mean 24-hour systolic BP (SBP) values from the baseline and at the week 8. Secondary endpoints included the change in the mean 24-hour diastolic BP values, the daytime and the nighttime mean BP values at week 8, the trough-to-peak (T/P) ratio and the smoothness index.
RESULTS
At week 8, the mean 24-hour SBP values significantly decreased in both groups; -10.5 ± 11.9 mmHg (p < 0.0001) in the fimasartan group and -5.5 ± 11.6 mmHg (p = 0.0307) in the valsartan group. The difference between two groups was 4.3 ± 2.9 mmHg but there was no statistical significance (p = 0.1392). The global T/P ratio in the fimasartan 30 mg groups were 0.48 and 0.40 in the valsartan 80 mg group, respectively (p = 0.3411). The most frequent adverse events (AEs) were acute pharyngitis and there were no cases of severe AEs.
CONCLUSIONS
In mild-to-moderate hypertensive patients, low dose (30 mg) fimasartan showed comparable 24-hour BP lowering efficacy compared with valsartan (80 mg). There was no difference in tolerability between two groups.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Efficacy and Safety of Nifedipine Gastrointestinal Therapeutic System(Adalat OROS) in Patients with Mild to Moderate Essential Hypertension
- Effect of Low-Dose Enalapril in Patients with Mild to Moderate Hypertension
- Manidipine Monotherapy in Patients with Mild to Moderate Essential Hypertension
- Hypotensive Effect of Perindopril in Patients with Essential Hypertension
- Dose-dependent Effect of Benidipine in Patients with mild moderate Hypertension
